A randomized, double-blind, placebo-controlled study of XL784 administered orally to subjects with albuminuria due to diabetic nephropathy.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 784 (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 16 Feb 2010 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Symphony Evolution added as trial sponser as reported by ClinicalTrials.gov.
- 16 Oct 2007 Status changed from recruiting to completed.